These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26121460)

  • 1. BASAL-BOLUS REGIMEN WITH INSULIN ANALOGUES VERSUS HUMAN INSULIN IN MEDICAL PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CONTROLLED TRIAL IN LATIN AMERICA.
    Bueno E; Benitez A; Rufinelli JV; Figueredo R; Alsina S; Ojeda A; Samudio S; Cáceres M; Argüello R; Romero F; Echagüe G; Pasquel F; Umpierrez GE
    Endocr Pract; 2015 Jul; 21(7):807-13. PubMed ID: 26121460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes.
    Bellido V; Suarez L; Rodriguez MG; Sanchez C; Dieguez M; Riestra M; Casal F; Delgado E; Menendez E; Umpierrez GE
    Diabetes Care; 2015 Dec; 38(12):2211-6. PubMed ID: 26459273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.
    Smiley D; Umpierrez GE; Hermayer K; Newton C; Jacobs S; Olson DE; Khan A; Rizzo M; Peng L; Reyes D; Cardona S; Fonseca V
    J Diabetes Complications; 2013; 27(6):637-41. PubMed ID: 23911535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes.
    Umpierrez GE; Hor T; Smiley D; Temponi A; Umpierrez D; Ceron M; Munoz C; Newton C; Peng L; Baldwin D
    J Clin Endocrinol Metab; 2009 Feb; 94(2):564-9. PubMed ID: 19017758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial.
    Umpierrez GE; Smiley D; Hermayer K; Khan A; Olson DE; Newton C; Jacobs S; Rizzo M; Peng L; Reyes D; Pinzon I; Fereira ME; Hunt V; Gore A; Toyoshima MT; Fonseca VA
    Diabetes Care; 2013 Aug; 36(8):2169-74. PubMed ID: 23435159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COMPARISON OF BASAL INSULIN REGIMENS ON GLYCEMIC VARIABILITY IN NONCRITICALLY ILL PATIENTS WITH TYPE 2 DIABETES.
    Haw JS; Farrokhi F; Smiley D; Peng L; Reyes D; Newton C; Pasquel FJ; Vellanki P; Umpierrez GE
    Endocr Pract; 2015 Dec; 21(12):1333-43. PubMed ID: 26307899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.
    Pasquel FJ; Lansang MC; Khowaja A; Urrutia MA; Cardona S; Albury B; Galindo RJ; Fayfman M; Davis G; Migdal A; Vellanki P; Peng L; Umpierrez GE
    Diabetes Care; 2020 Jun; 43(6):1242-1248. PubMed ID: 32273271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery).
    Umpierrez GE; Smiley D; Jacobs S; Peng L; Temponi A; Mulligan P; Umpierrez D; Newton C; Olson D; Rizzo M
    Diabetes Care; 2011 Feb; 34(2):256-61. PubMed ID: 21228246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).
    Umpierrez GE; Smiley D; Zisman A; Prieto LM; Palacio A; Ceron M; Puig A; Mejia R
    Diabetes Care; 2007 Sep; 30(9):2181-6. PubMed ID: 17513708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Intensive Versus Nonintensive Supplemental Insulin With a Basal-Bolus Insulin Regimen in Hospitalized Patients With Type 2 Diabetes: A Randomized Clinical Study.
    Vellanki P; Cardona S; Galindo RJ; Urrutia MA; Pasquel FJ; Davis GM; Fayfman M; Migdal A; Peng L; Umpierrez GE
    Diabetes Care; 2022 Oct; 45(10):2217-2223. PubMed ID: 35675498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial.
    Umpierrez GE; Jones S; Smiley D; Mulligan P; Keyler T; Temponi A; Semakula C; Umpierrez D; Peng L; Cerón M; Robalino G
    Diabetes Care; 2009 Jul; 32(7):1164-9. PubMed ID: 19366972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
    Dhital SM; Shenker Y; Meredith M; Davis DB
    Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
    Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
    Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for inpatient hypoglycemia during subcutaneous insulin therapy in non-critically ill patients with type 2 diabetes.
    Farrokhi F; Klindukhova O; Chandra P; Peng L; Smiley D; Newton C; Pasquel F; Fereira ME; Umpierrez G
    J Diabetes Sci Technol; 2012 Sep; 6(5):1022-9. PubMed ID: 23063027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study.
    Ilany J; Bhandari H; Nabriski D; Toledano Y; Konvalina N; Cohen O
    Diabetes Obes Metab; 2018 May; 20(5):1186-1192. PubMed ID: 29316176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
    Yeldandi RR; Lurie A; Baldwin D
    Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
    Mathur SK; Bansal A; Khan ZY
    J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.